Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Interest Expenses (2021 - 2025)

Oncology Institute (TOI) has disclosed Interest Expenses for 5 consecutive years, with $1.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Interest Expenses fell 13.71% year-over-year to $1.9 million, compared with a TTM value of $10.5 million through Sep 2025, up 27.32%, and an annual FY2024 reading of $7.5 million, up 10.61% over the prior year.
  • Interest Expenses was $1.9 million for Q3 2025 at Oncology Institute, up from $1.9 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $5.6 million in Q1 2025 and bottomed at $61000.0 in Q2 2022.
  • Average Interest Expenses over 5 years is $1.6 million, with a median of $1.9 million recorded in 2025.
  • The sharpest move saw Interest Expenses soared 2585.25% in 2023, then plummeted 39.82% in 2024.
  • Year by year, Interest Expenses stood at $81000.0 in 2021, then decreased by 24.69% to $61000.0 in 2022, then skyrocketed by 3081.97% to $1.9 million in 2023, then tumbled by 39.82% to $1.2 million in 2024, then skyrocketed by 64.38% to $1.9 million in 2025.
  • Business Quant data shows Interest Expenses for TOI at $1.9 million in Q3 2025, $1.9 million in Q2 2025, and $5.6 million in Q1 2025.